Literature DB >> 16782548

Reconstitution of Scid mice with CD4+CD25- T cells leads to rapid colitis: an improved model for pharmacologic testing.

Stine Kjellev1, Dorthe Lundsgaard, Steen Seier Poulsen, Helle Markholst.   

Abstract

Improved experimental colitis models are needed for evaluation of treatment strategies for IBD. Most current models either lack resemblance to IBD, are complicated to establish, or the colitis occurs slowly and inconsistently. Our aim was to characterize the course of colitis in C.B-17 Scid mice reconstituted with syngeneic CD25-depleted CD4+ cells, including the identification of useful biomarkers, and assessment of the similarities to IBD with focus on the relationship between colonic epithelial proliferation and inflammatory parameters. Groups of reconstituted and un-reconstituted mice were sacrificed weekly from week 1 to 4. Clinical signs of colitis occurred approximately 2 weeks after reconstitution. Disease onset and severity based on histopathology correlated well with the colonic weight:length ratio, fecal consistency score, presence of occult blood in feces, and fecal IL-1beta content. Loss in body weight was not apparent until colitis was well established and exhibited lower coefficient of correlation to the histologic score. Early colonic histopathology was dominated by epithelial hyperproliferation, loss of mucus and mild lymphoid infiltration. Epithelial hyperproliferation was paralleled by increased fecal soluble tumor necrosis factor receptor II content. Cytokines in colonic tissue homogenates exhibited a Th1-like profile. We conclude that adoptive transfer of CD4+CD25- T cells results in colitis resembling IBD with a rapid onset and limited variability between individuals. Purification of CD4+CD25- T cells is a simple procedure, and does not require flow-cytometric sorting. Fecal consistency score and colonic weight:length ratio are readily measurable and consistent disease parameters. This model is thus highly suitable for pharmacological testing of intervention strategies.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16782548     DOI: 10.1016/j.intimp.2006.04.017

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  15 in total

1.  The intestinotrophic peptide, GLP-2, counteracts the gastrointestinal atrophy in mice induced by the epidermal growth factor receptor inhibitor, erlotinib, and cisplatin.

Authors:  Andreas Rosén Rasmussen; Niels-Erik Viby; Kristine Juul Hare; Bolette Hartmann; Lars Thim; Jens Juul Holst; Steen Seier Poulsen
Journal:  Dig Dis Sci       Date:  2010-01-29       Impact factor: 3.199

2.  Heligmosomoides polygyrus bakeri infection activates colonic Foxp3+ T cells enhancing their capacity to prevent colitis.

Authors:  Long Hang; Arthur M Blum; Tommy Setiawan; Joseph P Urban; Korynn M Stoyanoff; Joel V Weinstock
Journal:  J Immunol       Date:  2013-07-12       Impact factor: 5.422

3.  Antibacterial and Immunosuppressive Effects of OPS-2071, a Candidate Therapy for Inflammatory Bowel Disease.

Authors:  Masayoshi Sato; Kazuyuki Fujii; Hiroko Takagi; Isao Shibuya; Daisuke Oka; Naomitsu Yamaya; Hiraku Hagita; Makoto Matsumoto; Katsuya Inagaki
Journal:  Dig Dis Sci       Date:  2021-08-31       Impact factor: 3.487

4.  NF-kappa B1 p105 regulates T cell homeostasis and prevents chronic inflammation.

Authors:  Mikyoung Chang; Andrew J Lee; Leo Fitzpatrick; Minying Zhang; Shao-Cong Sun
Journal:  J Immunol       Date:  2009-03-01       Impact factor: 5.422

5.  Histone deacetylase inhibitors modulate interleukin 6-dependent CD4+ T cell polarization in vitro and in vivo.

Authors:  Rainer Glauben; Elena Sonnenberg; Martin Wetzel; Paolo Mascagni; Britta Siegmund
Journal:  J Biol Chem       Date:  2014-01-13       Impact factor: 5.157

Review 6.  T cell transfer model of chronic colitis: concepts, considerations, and tricks of the trade.

Authors:  Dmitry V Ostanin; Jianxiong Bao; Iurii Koboziev; Laura Gray; Sherry A Robinson-Jackson; Melissa Kosloski-Davidson; V Hugh Price; Matthew B Grisham
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2008-11-25       Impact factor: 4.052

7.  Pharmacological Evaluation of the SCID T Cell Transfer Model of Colitis: As a Model of Crohn's Disease.

Authors:  Thomas Lindebo Holm; Steen Seier Poulsen; Helle Markholst; Stine Reedtz-Runge
Journal:  Int J Inflam       Date:  2012-02-19

8.  Endotoxic shock-expanded murine CD11c low CD45RB + regulatory dendritic cells modulate inflammatory T cell responses through multiple mechanisms.

Authors:  Xiaoqian Wang; Qingyang Wang; Xueying Zhang; Yajing Li; Jingyang Wang; Chunmei Hou; Juan Chen; Beifen Shen; Yanchun Shi; Jiyan Zhang
Journal:  Sci Rep       Date:  2015-05-29       Impact factor: 4.379

Review 9.  The gut microbiota in mouse models of inflammatory bowel disease.

Authors:  Kalliopi K Gkouskou; Chrysoula Deligianni; Christos Tsatsanis; Aristides G Eliopoulos
Journal:  Front Cell Infect Microbiol       Date:  2014-02-28       Impact factor: 5.293

10.  TIR-domain-containing adapter-inducing interferon-β (TRIF) regulates Th17-mediated intestinal immunopathology in colitis.

Authors:  S Kanagavelu; C Flores; J M Termini; R Riveron; L Romero; K Chung; J Ruiz; J Hyun; X Yuan; J Dagvadorj; M Fukata
Journal:  Mucosal Immunol       Date:  2014-07-30       Impact factor: 7.313

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.